文献速递淋巴瘤

现代治疗时代新诊断淋巴瘤患者的心血管疾病累积发病率与危险因素

Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era.
PubMed 文献 · Am J Hematol · 2021-05-27

该前瞻性队列纳入2002-2015年新诊断的3063例淋巴瘤患者,中位年龄59岁,10年心血管疾病累积发病率为10.7%(95%CI 9.5%-12.1%)。多变量分析显示年龄增长、男性、当前吸烟、BMI>30 kg/m2及任何蒽环类治疗均与心血管疾病风险显著相关。

要点

  • 淋巴瘤患者10年CVD累积发病率为10.7%,需重视长期心血管管理。
  • 蒽环类治疗与CVD风险增加相关(HR=1.57),尤其增加CHF和心律失常风险。
  • 吸烟、肥胖等传统心血管危险因素亦显著增加CVD风险,应积极干预。

核心结论

  • 在现代治疗时代,淋巴瘤幸存者中心血管疾病仍较常见,需要针对治疗和心血管危险因素采取预防措施。

研究设计与样本

  • 前瞻性队列研究,纳入2002-2015年新诊断的淋巴瘤患者(>18岁),排除诊断时已有心血管疾病者,最终分析3063例,中位年龄59岁(范围18-95)。

主要发现

  • 10年心血管疾病累积发病率为10.7%(95%CI 9.5%-12.1%),以死亡为竞争风险。
  • 多变量分析中,年龄增长(HR=1.05/年,p<0.001)、男性(HR=1.36,p=0.02)、当前吸烟(HR=2.10,p<0.001)、BMI>30 kg/m2(HR=1.45,p=0.01)及任何蒽环类治疗(HR=1.57,p<0.001)与CVD风险显著相关。
  • 调整心血管危险因素后,蒽环类与充血性心力衰竭风险增加相关(HR=2.71,p<0.001),与心律失常风险增加相关(HR=1.61,p<0.01),但与瓣膜性心脏病(HR=0.84,p=0.58)和急性冠脉综合征(HR=1.32,p=0.24)无显著相关。

临床怎么用

  • 对淋巴瘤患者应评估并管理传统心血管危险因素(吸烟、肥胖等),并重视蒽环类治疗后的心血管监测。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of cardiovascular disease (CVD) in long-term survivors of lymphoma is of increasing importance. Here, we characterize the cumulative incidence and risk factors for CVD in lymphoma patients diagnosed in the current treatment era. From 2002-2015, newly diagnosed lymphoma patients (>18 years) were enrollment into a prospective cohort study that captured incident CVD, consisting of congestive heart failure (CHF), acute coronary syndrome (ACS), valvular heart disease (VHD), and arrhythmia. The cumulative incidence of CVD was calculated with death modeled as a competing risk. We estimated the association of treatment with anthracyclines or radiotherapy and traditional CVD risk factors with incidence of CVD using hazard ratios (HR) and 95% confidence intervals (CI) estimated from Cox regression. After excluding prevalent CVD at lymphoma diagnosis, the study consisted of 3063 patients with a median age of 59 years (range 18-95). The cumulative incidence of CVD at 10-years was 10.7% (95% CI, 9.5%-12.1%). In multivariable analysis, increasing age (HR = 1.05 per year, p < 0.001), male sex (HR = 1.36, p = 0.02), current smoker (HR = 2.10, p < 0.001), BMI > 30 kg/m2 (HR = 1.45, p = 0.01), and any anthracycline treatment (HR = 1.57, p < 0.001) were all significantly associated with risk of CVD. Anthracyclines were associated with increased risk of CHF (HR = 2.71, p < 0.001) and arrhythmia (HR = 1.61, p < 0.01), but not VHD (HR = 0.84, p = 0.58) or ACS (HR = 1.32, p = 0.24) after adjustment for CVD risk factors. Even in the modern treatment era, CVD remains common in lymphoma survivors and preventive efforts are required that address both treatment and CVD risk factors.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Boddicker NJ, Larson MC, Castellino A, et al. Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. Am J Hematol. 2021. PMID: 33971040. doi:10.1002/ajh.26230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。